PT  - JOURNAL ARTICLE
AU  - Patyar, Sazal
AU  - Medhi, Bikash
TI  - Lacosamide, a newer antiepileptic
DP  - 2010 Jan 01
TA  - Neurosciences Journal
PG  - 3--6
VI  - 15
IP  - 1
4099  - http://nsj.org.sa/content/15/1/3.short
4100  - http://nsj.org.sa/content/15/1/3.full
SO  - Neurosciences (Riyadh)2010 Jan 01; 15
AB  - Lacosamide (LCM) is a newer antiepileptic drug with a dual mode of action. It selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation, and modulates collapsing response mediator protein 2 (CRMP-2). It has a high oral bioavailability of approximately 100%. It has shown potent and broad neuroprotective effects in vitro and in vivo animal models making it a potential candidate for long term treatment of epilepsy. In addition to this, it has demonstrated analgesic activity in various animal models. Apart from this, LCM has demonstrated potent effects in animal models for a variety of CNS disorders like schizophrenia and stress induced anxiety. Various safety pharmacology and toxicology studies have shown that LCM is well tolerated. Clinical trials have also suggested that LCM is a safe, effective, and well tolerated adjunctive treatment for reduction of seizure frequency in patients with highly refractory, partial seizures. Other potential indications of LCM are being investigated.